Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Fig. 1

Mean change from baseline in HAQ-DI scores in response to abatacept administered in combination with one csDMARD (a) All non-MTX csDMARDs pooled in individual interventional studies. (b) Data from the observational ACTION study. (c) Pooled analysis from the ATTAIN, ASSURE, and ARRIVE studies for individual csDMARDs. Error bars show 95% CI. ABA abatacept, AZA azathioprine, csDMARD conventional synthetic disease-modifying antirheumatic drug, HAQ-DI Health Assessment Questionnaire—Disability Index, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, SSZ sulfasalazine

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us